Wider market
Revvity
Formed from PerkinElmer's 2023 split, makes newborn screening tests, EUROIMMUN immunodiagnostics, and Signals research software for pharma R&D and clinical labs.
4 open roles
Formed from PerkinElmer's 2023 split, makes newborn screening tests, EUROIMMUN immunodiagnostics, and Signals research software for pharma R&D and clinical labs.